ERG and prostate cancer: Gene fusions involving the androgen-regulated serine protease TMPRSS2 and ERG, a member of the ETS family of transcription factors, occur in about 50 % of prostate cancers and result in strong AR-driven ERG protein overexpression [35, 36] and massive transcriptional changes [37–40].